| 영문 | anti-diuretic hormone; ADH | 한글 | 항이뇨호르몬 |
|---|---|---|---|
| 설명 | 뇌의 바닥에 붙어있는 호르몬을 주로 분비하는 작은 기관인 뇌하수체 후엽에서 분비되는 호르몬으로 콩팥에서 수분의 흡수를 촉진하여 체내에 수분의 양을 늘이는 역할을 한다. 동시에 혈관을 수축시키는 작용이 있어 혈압을 상승시키는 역할도 한다.    |
||
| 영문 | hormone | 한글 | 호르몬 |
|---|---|---|---|
| 설명 | 호르몬이란 특정한 내분비선에서 생성, 저장되어 있다가, 관류하는 혈액 중으로 분비된 다음 혈액에 실려 멀리 떨어져 있는 표적세포(호르몬이 작용을 나타내는 세포)에 이르러 그곳에서 특정한 기능을 발휘하는 물질을 말한다. 내분비샘이 아니더라도 어느 세포나 세포군에서 세포외액 중으로 분비된 다음 다른 세포에 가서 세포의 기능을 변동시키는 물질의 일부도 호르몬의 범주에 포함시키고 있으며 이들을 특별히 국소호르몬이라 부른다(예-아세틸콜린, 아드레날린, 콜레시스토키닌 등). 이에 비해서 특정 내분비샘에서 혈중으로 분비되는 진정한 의미의 호르몬들을 일반호르몬이라고 부른다. 호르몬을 흔히 3종의 무리로 분류를 하는데 아드레날린이나 thyroxine과 같이 아미노산의 유도체로 된 호르몬들(amine derivative), 많은 아미노산을 재료로 만들어졌거나 당단백으로 된 단백호르몬(peptide hormone), 그리고 콜레스테롤을 재료로 만들어진 지방호르몬(steroid hormone) 등으로 구분되며 이들은 대체로 종류에 따라 작용메커니즘을 달리하고 있다. |
||
| 영문 | luteinizing hormone(LH) | 한글 | 황체형성호르몬 |
|---|---|---|---|
| 설명 | 여성의 월경은 정해진 순서에 의해 일어나게 된다. 먼저 난포자극호르몬이 뇌에서 분비되어 여성의 난소를 자극하게 되면 난포가 자극받아 난포호르몬(에스트로젠)을 분비하게 되고 이것은 다시 되먹이기 메커니즘 의해 뇌에 작용을 하여 황체화호르몬이 뇌에서 분비되고 이것이 이른바 절정에 이르렀을 때, 난포에서 배란이 일어나게 된다. 이후 난포는 황체로 변하게 되며, 배란된 난자가 수정되지 아니하면, 황체는 황체호르몬(프로게스테론)을 분비한 뒤 퇴화되고 곧 이어 월경이 일어나게 된다. 이 일은 정상적인 대부분의 여성에서 28일을 주기로 일어나며, 대개 황체화호르몬 절정 이후 마지막은 14일로 일정하다고 한다. |
||
| PTH | parathormone; parathyroid; parathyroid hormone; percutaneous transhepatic drainage; phenylthiohydant... |
|---|---|
| TAPVR | Total Anomalous Pulmonary Venous Return = TAPVC 4 Types of TAPVR &... |
| PTHR | parathyroid hormone receptor |
| ALL | Acute Lymphocytic Leukemia 형태학적 분류 L1; Small, Homogenous(... |
| PTH | ParaThyroid Hormone |
| parathyroid hormonelike protein | A 140 amino acid protein secreted by some cancer cells; it causes hypercalcaemia. (05 Mar 2000) |
|---|---|
| parathyroid hormones | Polypeptide hormones (84 amino acid residues) secreted by the parathyroid glands, which promote release of calcium from bone to extracellular fluid by activating osteoblasts and inhibiting osteoclasts, indirectly promote increased intestinal absorption of calcium, and promote renal tubular reabsorption of calcium and increased renal excretion of phosphates. It is a major regulator of bone metabolism. Secretion of parathyroid hormone increases when the level of calcium in the extracellular fluid is low. Its action is opposed by calcitonin. (12 Dec 1998) |
| parathyroid insufficiency | <endocrinology> A term which describes the abnormally low production of parathyroid hormone by the parathyroid glands. Hypoparathyroidism may be congenital or occur in association with another disorder (autoimmune disease, haemochromatosis). Common symptoms are those of low blood calcium: muscle spasms, tetany, facial grimacing, laryngeal spasm and seizures. (11 Jan 1998) |
| parathyroid osteosis | Rarefying osteitis with fibrous degeneration and formation of cysts, and with the presence of fibrous nodules on the affected bones. It is due to marked osteoclastic activity secondary to hyperfunction of the parathyroid glands. (12 Dec 1998) |
| parathyroid tetany | Tetany due to lack of parathyroid function, spontaneous or following excision of the parathyroid glands. Synonym: hypoparathyroid tetany, parathyroprival tetany, tetania parathyreopriva. (05 Mar 2000) |
| chief cell of parathyroid gland | A round clear cell with a centrally located nucleus; secretes parathyroid hormone. (05 Mar 2000) |
| water-clear cell of parathyroid | A variety of chief cell, so-called because the cytoplasm contains much glycogen that is not preserved or stained in the usual preparation. Synonym: wasserhelle cell. (05 Mar 2000) |
| acetylcholine receptor antibodies | <neurology, investigation> A test used to measure the amount of antibodies to acetylcholine receptors on nerve endings. This is a diagnostic test for myasthenia gravis. A normal value is no antibodies in the bloodstream. Acetylcholine receptor (AChR) binding autoantibodies (i.e. Antibodies reactive with several epitopes other than the binding site for acetylcholine or alpha-bungarotoxin) are present in approximately 88% of patients with generalised myasthenia gravis, 70% of ocular myasthenia and in approximately 80% of myasthenia gravis in remission. Although serum concentrations of AChR binding autoantibodies do not in general correlate well with severity of weakness, there is typical decrease in concentration as weakness improves with immunosuppressive therapy. AChR blocking autoantibodies (i.e., antibodies reactive with the AChR binding site) are present in about 50% of patients with myasthenia gravis, 30% with ocular myasthenia gravis and 20% of myasthenia gravis in remission, AChR blocking autoantibodies are the only AChR autoantibodies present in about 1% of myasthenia gravis. AChR modulating autoantibodies (i.e., autoantibodies which cross-link AChRs and cause their removal from muscle membrane surfaces) are present in more than 90% of myasthenia gravis and occasionally are the only AchR autoantibodies detectable in mild, recent onset or ocular-restricted myasthenia gravis. Results for AChR modulating autoantibodies can be transiently false-positive due to curare-like drugs used during general anesthesia. AChR autoantibodies of one or more types are found in at least 80% of ocular myasthenia gravis. Although generally absent in neurological conditions other than myasthenia gravis(and consequently unlikely to cause confusion in neurodiagnosis), false-positive results for AChR autoantibodies occasionally occur in primary biliary cirrhosis, tardive dyskinesia, autoimmune thyroiditis, the elderly, amyotrophic lateral sclerosis patients treated with cobra venom and patients with thymoma in the absence of myasthenia gravis. Approximately 1% of patients with rheumatoid arthritis treated with D-penicillamine develop AChR autoantibodies and myasthenia gravis, both of which disappear when the drug is discontinued. Babies born to ~10% of myasthenia gravis mothers have a transient neonatal form of myasthenia gravis that responds well to anticholinesterase therapy and usually remits within 1 month as maternal IgG disappears. (29 Dec 1997) |
| amino acid receptor | <biochemistry> Ligand gated ion channels with specific receptors for amino acid transmitters. An extended protein superfamily that also includes subunits of the nicotinic acetylcholine receptor. (18 Nov 1997) |
| AMPA receptor | <cell biology> Glutamate operated ion channel. See: excitatory amino acid receptor channels. (05 Feb 1998) |
| ANP receptor | <molecular biology> Family of 3 receptors for atrial natriuretic peptide. ANP A and ANP B have intracellular guanylate cyclase and protein kinase like domains. ANP C, shares the extracellular ligand binding and transmembrane domains, but lacks the functional intracellular domains and is not thought to be involved in signal transduction. (18 Nov 1997) |
| asialoglycoprotein receptor | A surface receptor found in hepatocytes that binds galactose-terminal glycoproteins; thus, this receptor removes those proteins from circulation and they are in turn acted upon by hepatocyte lysosomes. (05 Mar 2000) |
| auditory receptor cells | Columnar cell's in the epithelium of the organ of Corti, having hairs (stereocilia) on their apical ends. See: Corti's cells. (05 Mar 2000) |
| beta-adrenergic receptor blocking agent | A class of drugs that compete with beta-adrenergic agonists for available receptor sites; some compete for both b1 and b2 receptors (e.g., propranolol) while others are primarily either b1 (e.g., metoprolol) or b2 blockers; used in the treatment of a variety of cardiovascular diseases where beta-adrenergic blockade is desirable. Synonym: beta-adrenergic receptor blocking agent, beta-adrenoreceptor antagonist, beta-blocker. (05 Mar 2000) |
| beta-adrenergic receptor kinase | <enzyme> Cyclic-AMP protein kinase which specifically phosphorylates the agonist-occupied form of beta-adrenergic receptor Registry number: EC 2.7.1.- Synonym: beta-ar kinase, beta-adrenergic receptor kinase 1, g-protein-coupled receptor kinase 2, grk2 (kinase), beta-adrenergic receptor kinase 2, beta-ar kinase 2 (26 Jun 1999) |